Department of Laboratory Medicine

Estrogen Receptor

The classic steroid hormone estrogen mediates its biological effects in cells through the estrogen receptor (ER), a member of the nuclear receptor family. ER is an intracellular transcription factor composed of six domains. There are two major isoforms, ERα and ERβ. Estrogen binding promotes its dimerization and nuclear localization. There, activated ER binds to DNA sequences termed estrogen response elements (EREs), in the regulatory regions of target genes. Several factors, including coactivators, corepressors and integrator proteins are important in ER-mediated transcription. It is becoming apparent that transcriptional regulation requires the recruitment by ER of multiple, distinct proteins that co-operate to achieve the required response.

Structural model of CaM bound to dimeric ERα (Zhang, et al JBC 2012)
Structural model of CaM bound to dimeric ERα (Zhang, et al JBC 2012). The main chain structure of the CaM/ER (287–552) complex generated using the ER-α structure (residues 287–305) attached to the dimeric LBD crystal structure (residues 305–552; Protein Data Bank code 1A52). One polypeptide chain of the ER-α dimer (orange) is bound to the CaM N-lobe (CaMN, cyan) and the other ER-α chain (white) is bound to the CaM C-lobe (CaMC, magenta). Estrogen (E2) is bound to the dimeric LBD (green), and Ca2+ is bound to CaM (yellow).

Calmodulin (CaM), a ubiquitous modulator of Ca2+ signaling, regulates the function of multiple, diverse proteins. Accumulating evidence supports a role for Ca2+ and calmodulin in breast carcinoma, as well as in estrogen action. Calmodulin contributes to the regulation of both ER-mediated transcriptional activation and ER degradation. For example, calmodulin binds directly to ER in a Ca2+-dependent manner and is required for formation of the ER-ERE complex. Evidence from our laboratory indicates that endogenous ER binds to endogenous calmodulin, attenuating the degradation of ER by sequestering it away from the ubiquitin degradation pathway. We subsequently documented that an interaction between calmodulin and ER in the nucleus is required for estrogen-stimulated ER transcriptional activation. Together, with the report that calmodulin antagonists inhibit the growth of human breast carcinoma cell lines, these findings suggest that Ca2+/calmodulin may be an important component of ER signaling pathways.

NOTE: PDF documents require the free Adobe Reader.

This page last updated on 06/09/2017

You are now leaving the NIH Clinical Center website.

This external link is provided for your convenience to offer additional information. The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site.

The NIH Clinical Center does not endorse, authorize or guarantee the sponsors, information, products or services described or offered at this external site. You will be subject to the destination site’s privacy policy if you follow this link.

More information about the NIH Clinical Center Privacy and Disclaimer policy is available at http://www.cc.nih.gov/disclaimers.html